Results 21 to 30 of about 1,678,208 (198)

Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective. [PDF]

open access: yesPharmaceutics
Background/Objectives: Obesity is a chronic, multifactorial condition driven by complex neuroendocrine and metabolic pathways that limit the long-term success of lifestyle interventions.
Ahmad I   +9 more
europepmc   +2 more sources

Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning. [PDF]

open access: yesDiabetes Obes Metab
ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Sztanek F   +3 more
europepmc   +2 more sources

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

open access: yesMolecular Metabolism, 2021
Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes and obesity. They elicit robust improvements in glycemic control and weight loss, combined with cardioprotection in individuals at risk of or with pre ...
Laurie L. Baggio, Daniel J. Drucker
doaj   +1 more source

Molecularly guided pharmacotherapy for obesity: emerging targets, clinical efficacy, and personalized therapeutic approaches. [PDF]

open access: yesFront Pharmacol
Obesity is a complex, chronic disease whose aetiology is complex and highly variable, and is linked to a network of neural, endocrine, adipose, genetic, epigenetic and metabolic pathways.
Mao J, Hu R.
europepmc   +2 more sources

Development of High Affinity Calcitonin Analog Fragments Targeting Extracellular Domains of Calcitonin Family Receptors

open access: yesBiomolecules, 2021
The calcitonin and amylin receptors (CTR and AMY receptors) are the drug targets for osteoporosis and diabetes treatment, respectively. Salmon calcitonin (sCT) and pramlintide were developed as peptide drugs that activate these receptors.
Sangmin Lee
doaj   +1 more source

Determinants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity. [PDF]

open access: yesObes Pillars
Introduction: The management of obesity changed significantly with the introduction of glucagon-like peptide-1 receptor agonists (GLP-1RAs). However, considerable interindividual variability in weight-loss response remains, and its determinants are ...
Ghosal S.
europepmc   +2 more sources

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat

open access: yesFrontiers in Endocrinology, 2021
The hormones amylin and calcitonin interact with receptors within the same family to exert their effects on the human organism. Calcitonin, derived from thyroid C cells, is known for its inhibitory effect on osteoclasts.
David S. Mathiesen   +10 more
doaj   +1 more source

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. [PDF]

open access: yesMetabol Open
Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss ...
Lempesis IG, Dalamaga M.
europepmc   +2 more sources

Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin

open access: yesFrontiers in Psychiatry, 2023
Alcohol use disorder (AUD) contributes substantially to global morbidity and mortality. Given the heterogenicity of this brain disease, available pharmacological treatments only display efficacy in sub-set of individuals.
Maximilian Tufvesson-Alm   +2 more
doaj   +1 more source

CiD agonists: Circular DNA-based agonists for the fine-tuning of receptor signaling [PDF]

open access: yes, 2022
Receptor dimerization geometry plays a significant role in signal transduction induced by growth factors and cytokines. A chemical strategy capable of controlling dimerization geometry provides a means for studying receptor activation mechanisms and ...
Momoko , Akiyama   +9 more
core   +2 more sources

Home - About - Disclaimer - Privacy